Protocol Ledger

NCT07361510 · Phase III · RECRUITING

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Interventional Phase III clinical trial protocol NCT07361510 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-12 Enrollment: 750 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07361510
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)750 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07361510
Protocol FieldVerified Registry Value
NCT IdentifierNCT07361510
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment750 participants (ESTIMATED)
Registered Start Date2026-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07361510
Hospital Research SiteLocationSite Profile
Beverly Hills Cancer CenterBeverly Hills, CAOpen Hospital Dossier ->
Cancer and Blood Specialty ClinicLos Alamitos, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI